pyrroles has been researched along with bibw 2992 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM | 1 |
| Ashrafi, GH; Modjtahedi, H; Seddon, AM; Stanley, A | 1 |
| Cil, O; Duan, T; Thiagarajah, JR; Verkman, AS | 1 |
| Carbasse, C; Jacot, W; Leenhardt, F; Perrier, C; Pinguet, F; Viala, M | 1 |
4 other study(ies) available for pyrroles and bibw 2992
| Article | Year |
|---|---|
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1 | 2013 |
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Enlargement; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Female; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1; src-Family Kinases | 2017 |
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.
Topics: Acetamides; Afatinib; Animals; Cell Membrane Permeability; Clotrimazole; Colon; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Disease Models, Animal; Epithelial Cells; ErbB Receptors; Female; Humans; Intestinal Mucosa; Neoplasms; Oxazines; Potassium Channel Blockers; Potassium Channels; Protein Kinase Inhibitors; Pyrimidinones; Pyrroles; Rats; Trityl Compounds | 2019 |
Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort.
Topics: Administration, Oral; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2022 |